FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileModerna, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MRNA
Moderna, Inc. Stock AnalysisComprehensive stock analysis for Moderna, Inc. (MRNA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMRNA
MRNA
Moderna, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MRNA
  1. Home
  2. Stocks
  3. Moderna, Inc.

Moderna, Inc.

🇺🇸MRNA•NASDAQ

Moderna, Inc.

🇺🇸MRNA•NASDAQ
Market cap
$87.10B
Sentiment

Your view on MRNA

Mkt Cap
$87.10B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Moderna, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Stéphane Bancel
Headquarters
200 Technology Square, Cambridge, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Stéphane Bancel
Headquarters
200 Technology Square, Cambridge, MA, US
Description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.

Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.

It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A.

The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Moderna, Inc. from FRC's valuation model, read against the market price. MRNA last traded at $215.27; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Moderna, Inc.. Starting points for Moderna, Inc.: EPS -$6.96, beta 0.90 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Moderna, Inc.. Moderna, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Moderna, Inc.. Trailing twelve-month EPS for Moderna, Inc. stands at -$6.96. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$122.73

average of 15 firms, last 12 months

 

$122.73

Low $25.00

Median $125.00

High $305.00

 

Analyst Ratings

Hold16 firms, last 12 months
  • Strong Buy0
  • Buy2
  • Hold9
  • Sell5
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate-$2.07-$1.76-$7.46-$4.33
Low estimate-$3.84-$2.01-$9.55-$6.96
High estimate-$1.36-$1.59-$2.94-$2.49
No. of analysts1151617
Year-ago EPS-$2.11-$3.40-$7.261—
Growth+2.0%+48.4%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$529.71M$302.19M$2.31B$2.65B
Low estimate$269.80M$123.44M$2.14B$2.11B
High estimate$678.72M$480.95M$2.52B$3.43B
No. of analysts931417
Year-ago revenue$678.00M$389.00M$1.94B—
Growth-21.9%-22.3%+18.7%—
Recent analyst actions15 rating and price-target changes, latest Nov 17, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, Investing; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Moderna, Inc.. Moderna, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MRNA20 companies · 8 funds
Compare MRNA with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ARCTArcturus Therapeutics Holdings Inc.Biotechnology$240M
  • BNTXBioNTech SEBiotechnology$21.1B
  • GSKGSK plcDrug Manufacturers - General$101.3B
  • INOInovio Pharmaceuticals, Inc.Biotechnology$97M
  • NVAXNovavax, Inc.Biotechnology$1.3B
  • OGENOragenics, Inc.Biotechnology$893,367
  • PCVXVaxcyte, Inc.Biotechnology$9.8B
  • PFEPfizer Inc.Drug Manufacturers - General$164.5B

More Biotechnology companies

  • MIRMMirum Pharmaceuticals, Inc.NASDAQ$6.0B
  • MISTMilestone Pharmaceuticals Inc.NASDAQ$45M
  • MLECMoolec Science S.A.NASDAQ$617,200
  • MLECWMoolec Science S.A.NASDAQ$76,243
  • MLLCFMolecular Partners AGOTC$131M
  • MLTXMoonLake ImmunotherapeuticsNASDAQ$998M
  • MLYSMineralys Therapeutics, Inc.NASDAQ$1.3B
  • MMIRFMedMira Inc.OTC$9M
  • MNKDMannKind CorporationNASDAQ$1.3B
  • MNOVMediciNova, Inc.NASDAQ$69M
  • MNPRMonopar Therapeutics Inc.NASDAQ$488M
  • MOLNMolecular Partners AGNASDAQ$103M

ETFs holding Moderna, Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.13%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.11%
  • QQQInvesco QQQ Trust, Series 1$446.1B in assets0.39%
  • IVViShares Core SP 500 ETF$852.9B in assets0.12%
  • IDNAiShares Genomics Immunology and Healthcare ETF$352M in assets13.13%
  • BBHVanEck Biotech ETF$536M in assets6.41%
  • SPHBInvesco S&P 500 High Beta ETF$782M in assets3.41%
  • XBIState Street SPDR S&P Biotech ETF$10.0B in assets2.37%

Largest holders first, then the funds most concentrated in MRNA.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Moderna, Inc., and how their positions are changing. At a $87.10B market value, institutional positions materially move Moderna, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Moderna, Inc. executives and directors. Shares of Moderna, Inc. have traded between $23.04 and $48.92 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Moderna, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Moderna, Inc.. Coverage tracks Moderna, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Moderna, Inc.

MRNA Analysis
Fair
Past5
Growth1
Health4
Profit1
Value1

News

Latest Market News